Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -64.07% is in line with its 3-year average of -64.21%, around the middle of its 3-year range (-77.40%–-55.04%).
5.12% above its 12-month average of -67.53%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -70.40%.
EBITDA MARGIN
-64.07%
EBITDA MARGIN AVG TTM
-67.53%
EBITDA MARGIN AVG 3Y
-63.84%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+5.12%
CURRENT VS 3Y AVG
-0.37%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$922.50M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$921.45M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$903.13M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$989.05M
EBITDA Margin
-1113.67%
TTM Avg
-2254.05%
3Y Avg
-2254.05%
5Y Avg
-2254.05%
Market Cap
$867.60M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | -64.07% | -67.53% | -63.84% | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | -189.51% | -701.94% | -497.69% | -575.23% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 20.95% | 21.20% | 20.44% | 19.67% |
| Bioventus Inc. (BVS)vs › | $915.95M | 18.58% | 12.56% | -0.37% | 4.16% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -358.45% | -358.45% | -358.45% | -358.45% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -1113.67% | -2254.05% | -2254.05% | -2254.05% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -37.08% | -66.80% | -66.80% | -66.80% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 13.41% | 11.95% | 15.57% | 17.13% |
Gross Margin
88.9%
EBITDA Margin
-64.1%
Operating Margin
-68.6%
Net Margin
-64.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -70.40% |
| 2026-03-31 | -77.40% |
| 2025-12-31 | -57.72% |
| 2025-09-30 | -63.11% |
| 2025-06-30 | -69.00% |
| 2025-03-31 | -67.70% |
| 2024-12-31 | -67.55% |
| 2024-09-30 | -56.38% |
| 2024-06-30 | -55.04% |
| 2024-03-31 | -55.04% |
| 2023-12-31 | -62.05% |
| 2023-09-30 | -59.44% |
| 2023-06-30 | -69.06% |
| 2023-03-31 | -69.06% |
